|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0205531,
umls-concept:C0226896,
umls-concept:C0238806,
umls-concept:C0244987,
umls-concept:C0330390,
umls-concept:C0442027,
umls-concept:C0442805,
umls-concept:C0935763,
umls-concept:C1511938,
umls-concept:C1515655,
umls-concept:C1527415,
umls-concept:C1533691,
umls-concept:C1554184,
umls-concept:C1999216,
umls-concept:C2745888
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2006-6-6
|
|
pubmed:abstractText |
GSK-3, a component of the canonical Wnt signaling pathway, is implicated in regulation of bone mass. The effect of a small molecule GSK-3 inhibitor was evaluated in pre-osteoblasts and in osteopenic rats. GSK-3 inhibitor induced osteoblast differentiation in vitro and increased markers of bone formation in vitro and in vivo with concomitant increased bone mass and strength in rats.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0884-0431
|
|
pubmed:author |
pubmed-author:BryantHenry UHU,
pubmed-author:EnglerThomasT,
pubmed-author:FrolikCharles ACA,
pubmed-author:HalladayDavid LDL,
pubmed-author:KriauciunasAidasA,
pubmed-author:KulkarniNalini HNH,
pubmed-author:LiuMinM,
pubmed-author:MaYanfei LYL,
pubmed-author:MartinT JohnTJ,
pubmed-author:NewM LML,
pubmed-author:OnyiaJude EJE,
pubmed-author:SatoMasahikoM,
pubmed-author:TianXioayanX,
pubmed-author:ZengQingqiangQ
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
910-20
|
|
pubmed:dateRevised |
2011-11-2
|
|
pubmed:meshHeading |
pubmed-meshheading:16753022-Administration, Oral,
pubmed-meshheading:16753022-Animals,
pubmed-meshheading:16753022-Biological Availability,
pubmed-meshheading:16753022-Biological Markers,
pubmed-meshheading:16753022-Bone Density,
pubmed-meshheading:16753022-Cell Differentiation,
pubmed-meshheading:16753022-Cell Proliferation,
pubmed-meshheading:16753022-Cells, Cultured,
pubmed-meshheading:16753022-Enzyme Inhibitors,
pubmed-meshheading:16753022-Female,
pubmed-meshheading:16753022-Glycogen Synthase Kinase 3,
pubmed-meshheading:16753022-Mesoderm,
pubmed-meshheading:16753022-Mice,
pubmed-meshheading:16753022-Osteoblasts,
pubmed-meshheading:16753022-Rats,
pubmed-meshheading:16753022-Rats, Sprague-Dawley,
pubmed-meshheading:16753022-Signal Transduction,
pubmed-meshheading:16753022-Weight-Bearing,
pubmed-meshheading:16753022-Wnt Proteins,
pubmed-meshheading:16753022-beta Catenin
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo.
|
|
pubmed:affiliation |
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA. jeo@lilly.com
|
|
pubmed:publicationType |
Journal Article
|
